State College, PA, based Investment company PFG Financial Advisors buys Colgate-Palmolive Co, BHP Billiton, SPDR S&P Insurance, WisdomTree MidCap Earnings Fund, General Electric Co, iShares Global Infrastructure ETF, Regions Financial, Ford Motor Co, Hormel Foods, iShares Core S&P Total U.S. Stock Market, sells iShares Core S&P Mid-Cap, iShares Core S&P Small-Cap, iShares Core MSCI EAFE, PIMCO Total Return Active Exchange-Traded Fund, Vanguard S&P 500 during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, PFG Financial Advisors. As of 2017-03-31, PFG Financial Advisors owns 187 stocks with a total value of $400 million. These are the details of the buys and sells.
New Purchases: KIE, IGF, RF, HRL, QCOM, IYE, GOOGL, ENB, BLK, AMAT, Added Positions: IVV, CL, BHP, EZM, GE, XOM, F, PEP, ITOT, VCSH, Reduced Positions: IJH, IJR, IEFA, BOND, VOO, IEF, IVE, QQQ, DBEF, VCIT, Sold Out: IEO, SPHQ, IYF, MINT, EMR, IHF, WU, CWB, BP, SE,
For the details of PFG Financial Advisors’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PFG+Financial+Advisors
Best Value Stocks To Watch For 2018: CytRx Corporation(CYTR)
- [By Roberto Pedone]
Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.
If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.
Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Best Value Stocks To Watch For 2018: Daiichi Sankyo Company, Limited (DSKYF)
- [By SEEKINGALPHA.COM]
According to Bob Radie (see transcript of January 9th teleconference), the company’s president and chief executive officer, a key consideration in the denial was the FDA’s granting, in November 2016, rival product MorphaBond three-year exclusivity for the intranasal route of abuse. Significantly, though, even though MorphaBond – developed by tiny, privately-owned Inspirion Delivery Technologies – was approved in October 2015, it is yet to be commercialized. An October 25, 2016, marketing agreement between Inspirion and Japan-based Daiichi Sankyo, Inc. (OTCPK:DSKYF) suggests MorphaBond could be launched in the near future, but it’s also important to note that the aforementioned exclusivity expires on October 2, 2018, at which point Egalet will be able to include the clinical data from its intranasal abuse potential study in its label.
Best Value Stocks To Watch For 2018: Houghton Mifflin Harcourt Company(HMHC)
- [By Peter Graham]
A long term performance chart shows shares of Barnes & Noble Education and global learning stockHoughton Mifflin Harcourt Co (NASDAQ: HMHC)underperforming while Barnes & Noble is back to breakeven levels and textbook stock Chegg Inc (NYSE: CHGG) has taken off:
- [By Peter Graham]
A long term performance chart shows Chegg Inc finallymovingabove IPO levels while potential performance benchmarks such as Houghton Mifflin Harcourt Co (NASDAQ: HMHC) and Barnes & Noble Education Inc (NYSE: BNED), a spin off from Barnes & Noble, Inc (NYSE: BKS), have seen their performance slip:
Best Value Stocks To Watch For 2018: BAE Systems PLC (BAESY)
- [By SEEKINGALPHA.COM]
Rheinmetall is currently trading at 15.7x forward earnings and 2.5x book value, a valuation that is closer to its automotive suppliers peers. Compared to its defense peers, its valuation is clearly cheap, as shown in the next table. This shows that Rheinmetall is usually benchmarked against its auto peers, even though 53% of its sales and 41% of operating income have come from its defense unit in the past year.
P/E P/BV Rheinmetall 15.7 2.5 Continental AG 12.4 2.9 Valeo 13.1 3.6 Brembo (OTC:BRBOF) 17.0 5.2 Leoni (OTC:LNNNY) 13.2 1.9 Auto Peers Average 14.3 3.2 Airbus 24.0 6.8 Leonardo 16.8 2.0 BAE Systems (OTCPK:BAESY) 18.5 5.7 Thales (OTCPK:THLEY) 22.4 4.3 Defense Sector Average 19.2 4.4
- [By WWW.THESTREET.COM]
BAE Systems (BAESY) and other defense stocks gained on Friday morning after President Donald Trump’s strike on Syria prompted investors to consider the possibility of greater Western involvement in the Syrian conflict.